LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1…
BELTSVILLE, Md., Jan. 10, 2025 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and…
Successfully completed a Phase 1 dose-escalation study demonstrating pan-mutant clinical activity, 95% target engagement and no grade 3 or 4…
MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed…
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™…
8th Sachs Annual Neuroscience Innovation Forum14th Annual LifeSci Advisors Corporate Access EventInvest Securities BioMed Forum 2025MidCap Events Frankfurt 2025Bio-Neuroscience 2025…
Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over…
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis…
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any…
LONDON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients…